Ranolazine as Antiarrhythmic Agent

Journal Title: BMH Medical Journal - Year 2019, Vol 6, Issue 2

Abstract

Ranolazine which has been approved for use an anti-anginal agent has been shown to have anti-arrhythmic properties both in experimental and clinical studies. Several case studies have shown the use of ranolazine in the treatment of atrial fibrillation, some even as a ‘pill in the pocket’ approach. MERLIN-TIMI 36, a randomized study of acute coronary syndrome, showed lower incidence of ventricular arrhythmias in the ranolazine arm. The most important anti-arrhythmic mechanism of of ranolazine is thought to be mediated by atrial-selective inhibition of peak sodium current (INaL) and inhibition of late INa in both atria and ventricles. The recent reclassification of anti-arrhythmic agents has designated drugs with this action in Class Id. There is clinical and experimental evidence for the potential use of ranolazine in congenital long QT syndrome 3. The recent RAID trial, a randomized evaluation of ranolazine in high risk patients with implantable cardioverter defibrillator and either ischemic or non-ischemic cardiomyopathy showed a marginally significant reduction of recurrent ventricular tachycardia and fibrillation. The potential risk of ranolazine-induced torsade de pointes in view of mild prolongation of QT interval has not been well confirmed, with only a single case report suggesting possible association. But the patient had other confounding factors including treatment with fluoxetine, amiodarone and diuretics causing hypokalemia and hypomagnesemia which are well known to cause torsade de pointes.

Authors and Affiliations

Johnson Francis, Charles Antzelevitch

Keywords

Related Articles

Attitude And Practices Of Subjects With Recent History Of Conjunctivitis, Regarding Treatment And Prevention Of The Disease

Conjunctivitis is considered as a mild disease affecting the eyes with epidemic potential. Supportive care and isolation helps to contain the disease and limit sequelae. Aims and objectives: To assess the attitude and...

Current Thinking In Pediatric Peri-operative Fluid Therapy

Proper perioperative fluid management is critical to maintain cardiovascular stability and adequate tissue perfusion. The volume and composition of fluid should be adapting to the physiology of the child and compensating...

Pregnancy With Huge Ovarian Cyst

Ovarian masses are not uncommon in pregnancy. Incidence of ovarian mass in pregnancy is reported to be about 1 in 1000. The most common ovarian masses seen in pregnancy are functional cysts of ovary; others being benign...

Post Hemi Thyroidectomy Hypothyroidism: Risk Factors and Course

Background: Risk factors for post hemithyroidectomy (HT) biochemical hypothyroidism (BH) and its course are not well understood. The aim of the study was to look at the incidence, risk factors and the course of BH after...

Coronary Lithoplasty: Shockwave Lithotripsy for the Coronaries

Calcified coronaries are always the nightmare of the interventional cardiologist. They cannot be easily dilated by balloon angioplasty and balloons might rupture while high pressure inflation is attempted, leading to cor...

Download PDF file
  • EP ID EP647507
  • DOI -
  • Views 121
  • Downloads 0

How To Cite

Johnson Francis, Charles Antzelevitch (2019). Ranolazine as Antiarrhythmic Agent. BMH Medical Journal, 6(2), 58-64. https://europub.co.uk/articles/-A-647507